On September 24, 2026 Persevere Therapeutics, Inc., a clinical-stage oncology company developing misetionamide — a first-in-class inhibitor of MYC, historically viewed as undruggable and coined ‘the grand orchestrator of cancer growth’ — reported that the first patient has been enrolled and treated in MIROC-1, the company’s Phase 2a clinical trial evaluating misetionamide as monotherapy in patients with platinum-resistant ovarian cancer (PROC). The first patient was treated at the Abramson Cancer Center of the University of Pennsylvania, one of four leading cancer centers participating in the trial.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
MIROC-1 (Misetionamide in Platinum-Resistant Ovarian Cancer) is an open-label, single-arm Phase 2a trial designed to evaluate the safety and efficacy of misetionamide as monotherapy in patients with platinum-resistant ovarian cancer. The trial will enroll 18 patients across four leading U.S. academic cancer centers. Participating sites include: University of Pennsylvania (Philadelphia, PA) — first patient treated; Rush University Medical Center / MD Anderson Cancer Center (Chicago, IL) — currently screening; Beth Israel Deaconess Medical Center / Harvard Medical School (Boston, MA) and University of Kansas Cancer Center (Kansas City, KS) — both expected to begin screening within the month.
"Treating the first patient in MIROC-1 is a defining moment for Persevere Therapeutics and, more importantly, for the women living with platinum-resistant ovarian cancer who urgently need new treatment options," said Seymour Fein, MD, Chief Medical Officer of Persevere Therapeutics. "Misetionamide’s unique ability to target MYC — a driver of tumor growth and proliferation that has proven impervious to prior therapeutic approaches — gives us genuine hope that we can meaningfully change outcomes for these patients. We are deeply grateful to our clinical partners, and above all, to the patients and families who are placing their trust in this program."
Platinum-resistant ovarian cancer represents one of the most challenging malignancies in oncology. According to the American Cancer Society approximately 21,000 women are diagnosed with ovarian cancer in the United States each year, and the majority will eventually develop platinum-resistance, at which point treatment options are limited and median survival is measured in months. 12,400 women die each year of ovarian cancer.
(Press release, Persevere Therapeutics, SEP 24, 2026, View Source [SID1234671068])